 | • レポートコード：MRC2-11QY10544 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は精巣腫瘍治療薬のグローバル市場について調査・分析したレポートです。種類別（シスプラチン、エトポシド、イホスファミド、パクリタキセル、ビンブラスチン、ブレオマイシン、ダクチノマイシン）市場規模、用途別（セミノーマ、ノンセミノーマ、ライディッヒ細胞がん、セルトリ細胞がん）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別精巣腫瘍治療薬の競争状況、市場シェア ・世界の精巣腫瘍治療薬市場：種類別市場規模 2015年-2020年（シスプラチン、エトポシド、イホスファミド、パクリタキセル、ビンブラスチン、ブレオマイシン、ダクチノマイシン） ・世界の精巣腫瘍治療薬市場：種類別市場規模予測 2021年-2026年（シスプラチン、エトポシド、イホスファミド、パクリタキセル、ビンブラスチン、ブレオマイシン、ダクチノマイシン） ・世界の精巣腫瘍治療薬市場：用途別市場規模 2015年-2020年（セミノーマ、ノンセミノーマ、ライディッヒ細胞がん、セルトリ細胞がん） ・世界の精巣腫瘍治療薬市場：用途別市場規模予測 2021年-2026年（セミノーマ、ノンセミノーマ、ライディッヒ細胞がん、セルトリ細胞がん） ・北米の精巣腫瘍治療薬市場分析：米国、カナダ ・ヨーロッパの精巣腫瘍治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの精巣腫瘍治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の精巣腫瘍治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの精巣腫瘍治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Bristol-Myers Squibb、Hospira、Ovation Pharmaceuticals、Teva Pharmaceutical、ZIOPHARM Oncology、Fresenius Kabi ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Testicular Cancer Drugs Market
The global Testicular Cancer Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Testicular Cancer Drugs Scope and Market Size
Testicular Cancer Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Testicular Cancer Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Testicular Cancer Drugs market is segmented into
Cisplatin
Etoposide
Ifosfamide
Paclitaxel
Vinblastine
Bleomycin
Dactinomycin
Segment by Application, the Testicular Cancer Drugs market is segmented into
Seminomas
Non-Seminomas
Leydig Cell Cancer
Sertoli Cell Cancer
Regional and Country-level Analysis
The Testicular Cancer Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Testicular Cancer Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Testicular Cancer Drugs Market Share Analysis
Testicular Cancer Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Testicular Cancer Drugs business, the date to enter into the Testicular Cancer Drugs market, Testicular Cancer Drugs product introduction, recent developments, etc.
The major vendors covered:
Bristol-Myers Squibb
Hospira
Ovation Pharmaceuticals
Teva Pharmaceutical
ZIOPHARM Oncology
Fresenius Kabi
…
1 Study Coverage
1.1 Testicular Cancer Drugs Product Introduction
1.2 Market Segments
1.3 Key Testicular Cancer Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Testicular Cancer Drugs Market Size Growth Rate by Type
1.4.2 Cisplatin
1.4.3 Etoposide
1.4.4 Ifosfamide
1.4.5 Paclitaxel
1.4.6 Vinblastine
1.4.7 Bleomycin
1.4.8 Dactinomycin
1.5 Market by Application
1.5.1 Global Testicular Cancer Drugs Market Size Growth Rate by Application
1.5.2 Seminomas
1.5.3 Non-Seminomas
1.5.4 Leydig Cell Cancer
1.5.5 Sertoli Cell Cancer
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Testicular Cancer Drugs Market Size, Estimates and Forecasts
2.1.1 Global Testicular Cancer Drugs Revenue 2015-2026
2.1.2 Global Testicular Cancer Drugs Sales 2015-2026
2.2 Global Testicular Cancer Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Testicular Cancer Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Testicular Cancer Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Testicular Cancer Drugs Competitor Landscape by Players
3.1 Testicular Cancer Drugs Sales by Manufacturers
3.1.1 Testicular Cancer Drugs Sales by Manufacturers (2015-2020)
3.1.2 Testicular Cancer Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Testicular Cancer Drugs Revenue by Manufacturers
3.2.1 Testicular Cancer Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Testicular Cancer Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Testicular Cancer Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Testicular Cancer Drugs Revenue in 2019
3.2.5 Global Testicular Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Testicular Cancer Drugs Price by Manufacturers
3.4 Testicular Cancer Drugs Manufacturing Base Distribution, Product Types
3.4.1 Testicular Cancer Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Testicular Cancer Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Testicular Cancer Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Testicular Cancer Drugs Market Size by Type (2015-2020)
4.1.1 Global Testicular Cancer Drugs Sales by Type (2015-2020)
4.1.2 Global Testicular Cancer Drugs Revenue by Type (2015-2020)
4.1.3 Testicular Cancer Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Testicular Cancer Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Testicular Cancer Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Testicular Cancer Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Testicular Cancer Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Testicular Cancer Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Testicular Cancer Drugs Market Size by Application (2015-2020)
5.1.1 Global Testicular Cancer Drugs Sales by Application (2015-2020)
5.1.2 Global Testicular Cancer Drugs Revenue by Application (2015-2020)
5.1.3 Testicular Cancer Drugs Price by Application (2015-2020)
5.2 Testicular Cancer Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Testicular Cancer Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Testicular Cancer Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Testicular Cancer Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Testicular Cancer Drugs by Country
6.1.1 North America Testicular Cancer Drugs Sales by Country
6.1.2 North America Testicular Cancer Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Testicular Cancer Drugs Market Facts & Figures by Type
6.3 North America Testicular Cancer Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Testicular Cancer Drugs by Country
7.1.1 Europe Testicular Cancer Drugs Sales by Country
7.1.2 Europe Testicular Cancer Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Testicular Cancer Drugs Market Facts & Figures by Type
7.3 Europe Testicular Cancer Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Testicular Cancer Drugs by Region
8.1.1 Asia Pacific Testicular Cancer Drugs Sales by Region
8.1.2 Asia Pacific Testicular Cancer Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Testicular Cancer Drugs Market Facts & Figures by Type
8.3 Asia Pacific Testicular Cancer Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Testicular Cancer Drugs by Country
9.1.1 Latin America Testicular Cancer Drugs Sales by Country
9.1.2 Latin America Testicular Cancer Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Testicular Cancer Drugs Market Facts & Figures by Type
9.3 Central & South America Testicular Cancer Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Testicular Cancer Drugs by Country
10.1.1 Middle East and Africa Testicular Cancer Drugs Sales by Country
10.1.2 Middle East and Africa Testicular Cancer Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Testicular Cancer Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Testicular Cancer Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Corporation Information
11.1.2 Bristol-Myers Squibb Description and Business Overview
11.1.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bristol-Myers Squibb Testicular Cancer Drugs Products Offered
11.1.5 Bristol-Myers Squibb Related Developments
11.2 Hospira
11.2.1 Hospira Corporation Information
11.2.2 Hospira Description and Business Overview
11.2.3 Hospira Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Hospira Testicular Cancer Drugs Products Offered
11.2.5 Hospira Related Developments
11.3 Ovation Pharmaceuticals
11.3.1 Ovation Pharmaceuticals Corporation Information
11.3.2 Ovation Pharmaceuticals Description and Business Overview
11.3.3 Ovation Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Ovation Pharmaceuticals Testicular Cancer Drugs Products Offered
11.3.5 Ovation Pharmaceuticals Related Developments
11.4 Teva Pharmaceutical
11.4.1 Teva Pharmaceutical Corporation Information
11.4.2 Teva Pharmaceutical Description and Business Overview
11.4.3 Teva Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Teva Pharmaceutical Testicular Cancer Drugs Products Offered
11.4.5 Teva Pharmaceutical Related Developments
11.5 ZIOPHARM Oncology
11.5.1 ZIOPHARM Oncology Corporation Information
11.5.2 ZIOPHARM Oncology Description and Business Overview
11.5.3 ZIOPHARM Oncology Sales, Revenue and Gross Margin (2015-2020)
11.5.4 ZIOPHARM Oncology Testicular Cancer Drugs Products Offered
11.5.5 ZIOPHARM Oncology Related Developments
11.6 Fresenius Kabi
11.6.1 Fresenius Kabi Corporation Information
11.6.2 Fresenius Kabi Description and Business Overview
11.6.3 Fresenius Kabi Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Fresenius Kabi Testicular Cancer Drugs Products Offered
11.6.5 Fresenius Kabi Related Developments
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Corporation Information
11.1.2 Bristol-Myers Squibb Description and Business Overview
11.1.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bristol-Myers Squibb Testicular Cancer Drugs Products Offered
11.1.5 Bristol-Myers Squibb Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Testicular Cancer Drugs Market Estimates and Projections by Region
12.1.1 Global Testicular Cancer Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Testicular Cancer Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Testicular Cancer Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Testicular Cancer Drugs Sales Forecast (2021-2026)
12.2.2 North America: Testicular Cancer Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Testicular Cancer Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Testicular Cancer Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Testicular Cancer Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Testicular Cancer Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Testicular Cancer Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Testicular Cancer Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Testicular Cancer Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Testicular Cancer Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Testicular Cancer Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Testicular Cancer Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Testicular Cancer Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Testicular Cancer Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Testicular Cancer Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Testicular Cancer Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Testicular Cancer Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Testicular Cancer Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Testicular Cancer Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Testicular Cancer Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Testicular Cancer Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Testicular Cancer Drugs Market Segments
Table 2. Ranking of Global Top Testicular Cancer Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Testicular Cancer Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Cisplatin
Table 5. Major Manufacturers of Etoposide
Table 6. Major Manufacturers of Ifosfamide
Table 7. Major Manufacturers of Paclitaxel
Table 8. Major Manufacturers of Vinblastine
Table 9. Major Manufacturers of Bleomycin
Table 10. Major Manufacturers of Dactinomycin
Table 11. Global Testicular Cancer Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 12. Global Testicular Cancer Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 13. Global Testicular Cancer Drugs Sales by Regions 2015-2020 (K Units)
Table 14. Global Testicular Cancer Drugs Sales Market Share by Regions (2015-2020)
Table 15. Global Testicular Cancer Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 16. Global Testicular Cancer Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 17. Global Testicular Cancer Drugs Sales Share by Manufacturers (2015-2020)
Table 18. Global Testicular Cancer Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 19. Global Testicular Cancer Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Testicular Cancer Drugs as of 2019)
Table 20. Testicular Cancer Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 21. Testicular Cancer Drugs Revenue Share by Manufacturers (2015-2020)
Table 22. Key Manufacturers Testicular Cancer Drugs Price (2015-2020) (USD/Units)
Table 23. Testicular Cancer Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Testicular Cancer Drugs Product Type
Table 25. Date of International Manufacturers Enter into Testicular Cancer Drugs Market
Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 27. Global Testicular Cancer Drugs Sales by Type (2015-2020) (K Units)
Table 28. Global Testicular Cancer Drugs Sales Share by Type (2015-2020)
Table 29. Global Testicular Cancer Drugs Revenue by Type (2015-2020) (US$ Million)
Table 30. Global Testicular Cancer Drugs Revenue Share by Type (2015-2020)
Table 31. Testicular Cancer Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Units)
Table 32. Global Testicular Cancer Drugs Sales by Application (2015-2020) (K Units)
Table 33. Global Testicular Cancer Drugs Sales Share by Application (2015-2020)
Table 34. North America Testicular Cancer Drugs Sales by Country (2015-2020) (K Units)
Table 35. North America Testicular Cancer Drugs Sales Market Share by Country (2015-2020)
Table 36. North America Testicular Cancer Drugs Revenue by Country (2015-2020) (US$ Million)
Table 37. North America Testicular Cancer Drugs Revenue Market Share by Country (2015-2020)
Table 38. North America Testicular Cancer Drugs Sales by Type (2015-2020) (K Units)
Table 39. North America Testicular Cancer Drugs Sales Market Share by Type (2015-2020)
Table 40. North America Testicular Cancer Drugs Sales by Application (2015-2020) (K Units)
Table 41. North America Testicular Cancer Drugs Sales Market Share by Application (2015-2020)
Table 42. Europe Testicular Cancer Drugs Sales by Country (2015-2020) (K Units)
Table 43. Europe Testicular Cancer Drugs Sales Market Share by Country (2015-2020)
Table 44. Europe Testicular Cancer Drugs Revenue by Country (2015-2020) (US$ Million)
Table 45. Europe Testicular Cancer Drugs Revenue Market Share by Country (2015-2020)
Table 46. Europe Testicular Cancer Drugs Sales by Type (2015-2020) (K Units)
Table 47. Europe Testicular Cancer Drugs Sales Market Share by Type (2015-2020)
Table 48. Europe Testicular Cancer Drugs Sales by Application (2015-2020) (K Units)
Table 49. Europe Testicular Cancer Drugs Sales Market Share by Application (2015-2020)
Table 50. Asia Pacific Testicular Cancer Drugs Sales by Region (2015-2020) (K Units)
Table 51. Asia Pacific Testicular Cancer Drugs Sales Market Share by Region (2015-2020)
Table 52. Asia Pacific Testicular Cancer Drugs Revenue by Region (2015-2020) (US$ Million)
Table 53. Asia Pacific Testicular Cancer Drugs Revenue Market Share by Region (2015-2020)
Table 54. Asia Pacific Testicular Cancer Drugs Sales by Type (2015-2020) (K Units)
Table 55. Asia Pacific Testicular Cancer Drugs Sales Market Share by Type (2015-2020)
Table 56. Asia Pacific Testicular Cancer Drugs Sales by Application (2015-2020) (K Units)
Table 57. Asia Pacific Testicular Cancer Drugs Sales Market Share by Application (2015-2020)
Table 58. Latin America Testicular Cancer Drugs Sales by Country (2015-2020) (K Units)
Table 59. Latin America Testicular Cancer Drugs Sales Market Share by Country (2015-2020)
Table 60. Latin Americaa Testicular Cancer Drugs Revenue by Country (2015-2020) (US$ Million)
Table 61. Latin America Testicular Cancer Drugs Revenue Market Share by Country (2015-2020)
Table 62. Latin America Testicular Cancer Drugs Sales by Type (2015-2020) (K Units)
Table 63. Latin America Testicular Cancer Drugs Sales Market Share by Type (2015-2020)
Table 64. Latin America Testicular Cancer Drugs Sales by Application (2015-2020) (K Units)
Table 65. Latin America Testicular Cancer Drugs Sales Market Share by Application (2015-2020)
Table 66. Middle East and Africa Testicular Cancer Drugs Sales by Country (2015-2020) (K Units)
Table 67. Middle East and Africa Testicular Cancer Drugs Sales Market Share by Country (2015-2020)
Table 68. Middle East and Africa Testicular Cancer Drugs Revenue by Country (2015-2020) (US$ Million)
Table 69. Middle East and Africa Testicular Cancer Drugs Revenue Market Share by Country (2015-2020)
Table 70. Middle East and Africa Testicular Cancer Drugs Sales by Type (2015-2020) (K Units)
Table 71. Middle East and Africa Testicular Cancer Drugs Sales Market Share by Type (2015-2020)
Table 72. Middle East and Africa Testicular Cancer Drugs Sales by Application (2015-2020) (K Units)
Table 73. Middle East and Africa Testicular Cancer Drugs Sales Market Share by Application (2015-2020)
Table 74. Bristol-Myers Squibb Corporation Information
Table 75. Bristol-Myers Squibb Description and Major Businesses
Table 76. Bristol-Myers Squibb Testicular Cancer Drugs Production (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 77. Bristol-Myers Squibb Product
Table 78. Bristol-Myers Squibb Recent Development
Table 79. Hospira Corporation Information
Table 80. Hospira Description and Major Businesses
Table 81. Hospira Testicular Cancer Drugs Production (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 82. Hospira Product
Table 83. Hospira Recent Development
Table 84. Ovation Pharmaceuticals Corporation Information
Table 85. Ovation Pharmaceuticals Description and Major Businesses
Table 86. Ovation Pharmaceuticals Testicular Cancer Drugs Production (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 87. Ovation Pharmaceuticals Product
Table 88. Ovation Pharmaceuticals Recent Development
Table 89. Teva Pharmaceutical Corporation Information
Table 90. Teva Pharmaceutical Description and Major Businesses
Table 91. Teva Pharmaceutical Testicular Cancer Drugs Production (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 92. Teva Pharmaceutical Product
Table 93. Teva Pharmaceutical Recent Development
Table 94. ZIOPHARM Oncology Corporation Information
Table 95. ZIOPHARM Oncology Description and Major Businesses
Table 96. ZIOPHARM Oncology Testicular Cancer Drugs Production (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 97. ZIOPHARM Oncology Product
Table 98. ZIOPHARM Oncology Recent Development
Table 99. Fresenius Kabi Corporation Information
Table 100. Fresenius Kabi Description and Major Businesses
Table 101. Fresenius Kabi Testicular Cancer Drugs Production (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 102. Fresenius Kabi Product
Table 103. Fresenius Kabi Recent Development
Table 104. Global Testicular Cancer Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 105. Global Testicular Cancer Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 106. Global Testicular Cancer Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 107. Global Testicular Cancer Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 108. North America: Testicular Cancer Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 109. North America: Testicular Cancer Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 110. Europe: Testicular Cancer Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 111. Europe: Testicular Cancer Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 112. Asia Pacific: Testicular Cancer Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 113. Asia Pacific: Testicular Cancer Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 114. Latin America: Testicular Cancer Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 115. Latin America: Testicular Cancer Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 116. Middle East and Africa: Testicular Cancer Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 117. Middle East and Africa: Testicular Cancer Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 118. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 119. Key Challenges
Table 120. Market Risks
Table 121. Main Points Interviewed from Key Testicular Cancer Drugs Players
Table 122. Testicular Cancer Drugs Customers List
Table 123. Testicular Cancer Drugs Distributors List
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Testicular Cancer Drugs Product Picture
Figure 2. Global Testicular Cancer Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Cisplatin Product Picture
Figure 4. Etoposide Product Picture
Figure 5. Ifosfamide Product Picture
Figure 6. Paclitaxel Product Picture
Figure 7. Vinblastine Product Picture
Figure 8. Bleomycin Product Picture
Figure 9. Dactinomycin Product Picture
Figure 10. Global Testicular Cancer Drugs Sales Market Share by Application in 2020 & 2026
Figure 11. Seminomas
Figure 12. Non-Seminomas
Figure 13. Leydig Cell Cancer
Figure 14. Sertoli Cell Cancer
Figure 15. Testicular Cancer Drugs Report Years Considered
Figure 16. Global Testicular Cancer Drugs Market Size 2015-2026 (US$ Million)
Figure 17. Global Testicular Cancer Drugs Sales 2015-2026 (K Units)
Figure 18. Global Testicular Cancer Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 19. Global Testicular Cancer Drugs Sales Market Share by Region (2015-2020)
Figure 20. Global Testicular Cancer Drugs Sales Market Share by Region in 2019
Figure 21. Global Testicular Cancer Drugs Revenue Market Share by Region (2015-2020)
Figure 22. Global Testicular Cancer Drugs Revenue Market Share by Region in 2019
Figure 23. Global Testicular Cancer Drugs Sales Share by Manufacturer in 2019
Figure 24. The Top 10 and 5 Players Market Share by Testicular Cancer Drugs Revenue in 2019
Figure 25. Testicular Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 26. Global Testicular Cancer Drugs Sales Market Share by Type (2015-2020)
Figure 27. Global Testicular Cancer Drugs Sales Market Share by Type in 2019
Figure 28. Global Testicular Cancer Drugs Revenue Market Share by Type (2015-2020)
Figure 29. Global Testicular Cancer Drugs Revenue Market Share by Type in 2019
Figure 30. Global Testicular Cancer Drugs Market Share by Price Range (2015-2020)
Figure 31. Global Testicular Cancer Drugs Sales Market Share by Application (2015-2020)
Figure 32. Global Testicular Cancer Drugs Sales Market Share by Application in 2019
Figure 33. Global Testicular Cancer Drugs Revenue Market Share by Application (2015-2020)
Figure 34. Global Testicular Cancer Drugs Revenue Market Share by Application in 2019
Figure 35. North America Testicular Cancer Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 36. North America Testicular Cancer Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 37. North America Testicular Cancer Drugs Sales Market Share by Country in 2019
Figure 38. North America Testicular Cancer Drugs Revenue Market Share by Country in 2019
Figure 39. U.S. Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 40. U.S. Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. Canada Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 42. Canada Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 43. North America Testicular Cancer Drugs Market Share by Type in 2019
Figure 44. North America Testicular Cancer Drugs Market Share by Application in 2019
Figure 45. Europe Testicular Cancer Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 46. Europe Testicular Cancer Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 47. Europe Testicular Cancer Drugs Sales Market Share by Country in 2019
Figure 48. Europe Testicular Cancer Drugs Revenue Market Share by Country in 2019
Figure 49. Germany Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 50. Germany Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. France Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 52. France Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. U.K. Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 54. U.K. Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Italy Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 56. Italy Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Russia Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 58. Russia Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Europe Testicular Cancer Drugs Market Share by Type in 2019
Figure 60. Europe Testicular Cancer Drugs Market Share by Application in 2019
Figure 61. Asia Pacific Testicular Cancer Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 62. Asia Pacific Testicular Cancer Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 63. Asia Pacific Testicular Cancer Drugs Sales Market Share by Region in 2019
Figure 64. Asia Pacific Testicular Cancer Drugs Revenue Market Share by Region in 2019
Figure 65. China Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 66. China Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. Japan Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 68. Japan Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. South Korea Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 70. South Korea Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. India Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 72. India Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Australia Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 74. Australia Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Taiwan Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 76. Taiwan Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Indonesia Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 78. Indonesia Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Thailand Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 80. Thailand Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Malaysia Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 82. Malaysia Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Philippines Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 84. Philippines Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Vietnam Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 86. Vietnam Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 87. Asia Pacific Testicular Cancer Drugs Market Share by Type in 2019
Figure 88. Asia Pacific Testicular Cancer Drugs Market Share by Application in 2019
Figure 89. Latin America Testicular Cancer Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 90. Latin America Testicular Cancer Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 91. Latin America Testicular Cancer Drugs Sales Market Share by Country in 2019
Figure 92. Latin America Testicular Cancer Drugs Revenue Market Share by Country in 2019
Figure 93. Mexico Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 94. Mexico Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Brazil Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 96. Brazil Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Argentina Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 98. Argentina Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 99. Latin America Testicular Cancer Drugs Market Share by Type in 2019
Figure 100. Latin America Testicular Cancer Drugs Market Share by Application in 2019
Figure 101. Middle East and Africa Testicular Cancer Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 102. Middle East and Africa Testicular Cancer Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 103. Middle East and Africa Testicular Cancer Drugs Sales Market Share by Country in 2019
Figure 104. Middle East and Africa Testicular Cancer Drugs Revenue Market Share by Country in 2019
Figure 105. Turkey Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 106. Turkey Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Saudi Arabia Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 108. Saudi Arabia Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. U.A.E Testicular Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 110. U.A.E Testicular Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 111. Middle East and Africa Testicular Cancer Drugs Market Share by Type in 2019
Figure 112. Middle East and Africa Testicular Cancer Drugs Market Share by Application in 2019
Figure 113. North America Testicular Cancer Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 114. North America Testicular Cancer Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Europe Testicular Cancer Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 116. Europe Testicular Cancer Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Asia Pacific Testicular Cancer Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 118. Asia Pacific Testicular Cancer Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Latin America Testicular Cancer Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 120. Latin America Testicular Cancer Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Middle East and Africa Testicular Cancer Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 122. Middle East and Africa Testicular Cancer Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 123. Porter's Five Forces Analysis
Figure 124. Channels of Distribution
Figure 125. Distributors Profiles
Figure 126. Bottom-up and Top-down Approaches for This Report
Figure 127. Data Triangulation
Figure 128. Key Executives Interviewed
頭頸部がん治療薬/治療の世界市場（～2026年） Head and neck cancer is a group of cancers that starts in the mouth, nose, throat, larynx, sinuses, or salivary glands. Current trends indicate that rising geriatric population worldwide, growing cases of target diseases, and availability of improved healthcare services due to government and private…- 腎臓/腎がん治療薬の世界市場（～2026年） Kidney/Renal Cancer Drugs are used to cure kidney cancers. The market is primarily driven by lifestyle affecting factors such as reduced physical activity, excessive smoking and drinking. Rising aging population and the mounting prevalence of kidney cancer cases are some of the additional factors bo…
- 尿管がん治療薬の世界市場（～2026年） Market Analysis and Insights: Global Ureter Cancer Drugs Market The global Ureter Cancer Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Ureter Cancer Drugs Scope and Market Size Ureter Cancer Drugs market is seg…
- 腫瘍学/がん治療薬の世界市場（～2026年） Cancer Treatment Drugs are used to treat malignancies, or cancerous growths. Depending on the technology it cans classification into Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy and Others. Oncology Drugs is widely used For Blood Cancer, Breast Cancer, Gastroint…
- 胃がん治療薬の世界市場（～2026年） Gastric cancer drugs are used to treat malignancies, or cancerous growths. The APAC region to account for the highest market share during the forecast period. Much of this region’s growth can be attributed to the increasing demand for better healthcare infrastructure, which results in its massive ma…